STOCKS TELEGRAPH

Tag: Kura stock

  • KURA Oncology’s Stock Climbs As New Drug Development Takes Center Stage

    KURA Oncology’s Stock Climbs As New Drug Development Takes Center Stage

    During the current market session, Kura Oncology, Inc. (NASDAQ: KURA) is observing a significant upsurge in its stock, demonstrating a notable escalation of 8.53% to $19.02. This positive movement in KURA shares can be attributed to the recent strides made by the company in the realm of novel drug development.

    Today, Kura Oncology (KURA) has officially declared that its investigational drug, ziftomenib, has received Breakthrough Therapy Designation (BTD) from the U.S. Food and Drug Administration (FDA). This designation has been granted for the treatment of patients grappling with relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML).

    In patients with R/R NPM1-mutant AML, the FDA granted BTD based on Kura’s KOMET-001 clinical research. BTD is accorded to drugs that target serious or life-threatening conditions and for which preliminary clinical evidence suggests a potential for substantial improvement over existing therapies on clinically significant endpoints.

    This designation is geared towards expediting the development and evaluation of drugs, entailing a dedicated commitment from FDA senior management and seasoned review personnel, alongside eligibility for rolling review and priority review. The FDA’s decision underscores the promising potential of the drug as an innovative therapeutic solution for patients grappling with relapsed/refractory NPM1-mutant AML.

    NPM1-mutant AML accounts for approximately 30% of new AML cases annually. The awarding of this designation underscores the substantial unmet need in treating NPM1-mutant AML, where no targeted therapy has been approved to date, while highlighting the potential of ziftomenib to offer considerable improvement over existing treatment modalities.

    Remaining steadfast in its commitment, Kura Oncology is dedicated to expediting the availability of ziftomenib to the market, catering to the urgent requirements of patients in need of effective treatments. The company is poised to conclude the registration-directed trial of ziftomenib in R/R NPM1-mutant AML by mid-2024.

    Furthermore, ziftomenib is undergoing evaluation in conjunction with current standard treatments, such as venetoclax/azacitidine or cytarabine plus daunorubicin in NPM1-mutant and KMT2A-rearranged AML (KOMET-007), and with gilteritinib, FLAG-IDA, or LDAC in NPM1-mutant and KMT2A-rearranged AML (KOMET-008).

  • Early Morning Vibes: 4 Top Trending Stocks To Watch For Monday

    Early Morning Vibes: 4 Top Trending Stocks To Watch For Monday

    Last week indices in the United States managed to set fresh records on the price boards. Interestingly, we saw Wall Street indices initially take a dip on Friday. This dip came after the US government announced that employment declined in December. Contrary to expectations, the number of jobs fell by 140,000, while economists had expected an increase of about 50,000 jobs. The question is whether this has halted the recovery of the labor market or whether this effect is temporary due to stricter corona measures.

    In response to the bad jobs report, upcoming president Joe Biden announced that he would come up with additional stimulus measures to get the US economy through the corona crisis. The stock markets recovered towards the close and eventually, the indices closed at the highest point of the day. The S&P 500 closed with a gain of 0.55% at 3,824 points and the Nasdaq gained 1.03% at 13,202 points.

    Earnings Update

    This week the earnings season will officially start, and the American major banks will give the starting shot. Citigroup, JPMorgan Chase and Wells Fargo, among others, will open the books this Friday. On Tuesday, Just Eat Takeaway, Blackrock, and Alcoa will be the first to open the books.

    Corporate News

    Twitter’s share price closed 1.61% lower on Friday. According to Twitter, Donald Trump incites violence and Facebook and Instagram also blocked Trump’s accounts until at least until after the inauguration of Joe Biden. Trump was a very active twitterer and had about 88 million followers.

    Many celebrities are happy with the ban, but others point to censorship. Big Tech is also accused of restricting freedom of speech. The question is whether Trump will soon take a formal approach to Big Tech.

    Today Top Movers

    Castor Maritime Inc (CTRM), a Marine Shipping company, soared about 7.49% ‎at $0.21 in pre-market trading Monday following the declaration of pricing of $26.0 million registered direct offering. 

    ‎Nio Inc (NIO) share price jumped 6.26% to $62.61 during the early morning ‎trading session on Monday. 

    ‎Sundial Growers Inc (SNDL) stock ascended 15.66% at $0.79 in the pre-market trading today.

    ‎Avinger Inc (AVGR) gained over 28.40% at $1.15 in pre-market ‎trading on Monday.‎‎

    Top Upgrades & Downgrades


    RBC Capital turned bullish on Royal Gold Inc. (RGLD), upgrading the stock to “Outperform” and assigning a $150.0 price target, representing a potential upside of 42.05% from Friday’s close. 

    Boot Barn Holdings Inc. (BOOT) has won the favor of JP Morgan’s equity research team. The firm upgraded the shares from Neutral to Overweight and moved their price target to $60.0, suggesting 23.48% additional upside for the stock. 

    Anaplan Inc. (PLAN) received an upgrade from analysts at Jefferies, who also set their one-year price target on the stock to $85.0. They changed their rating on PLAN to Buy from Hold in a recently issued research note. 

    Earlier Monday Piper Sandler reduced its rating on salesforce.com inc. (CRM) stock to Neutral from Overweight and assigned the price target to $242.0. With shares trading at around $222.04, the Wall Street firm thinks salesforce.com’s stock could add than 8.94%.
     

    Ladenburg Thalmann analysts reduced their investment ratings, saying in research reports covered by the media that it’s rating for Lipocine Inc. (LPCN) has been changed to Buy from Neutral and the new price target is set at $3. 

    Analysts at BMO Capital downgraded Archer-Daniels-Midland Company (ADM)’s stock to Market Perform from Outperform on Monday.

    Latest Insider Activity

    Sunrun Inc. (RUN) Chairman Fenster Edward Harris announced the sale of shares taking place on Jan 07 at $89.10 for some 50,000 shares. The total came to more than $4.46 million. 

    Chegg Inc. (CHGG) PRESIDENT, CEO & CO-CHAIRMAN ROSENSWEIG DANIEL sold on Jan 07 a total 1,907,090 shares at $91.14 on average. The insider’s sale generated proceeds of almost $2.55 million.
     

    Hall of Fame Resort & Entertainment Company (HOFV) Director Lichter Stuart declared the purchase of shares taking place on Dec 29 at $1.40 for some 10,813,774 shares. The transaction amount was around $15.14 million. 

    Aileron Therapeutics Inc. (ALRN) Satter Muneer A bought on Jan 08 a total of 16,609,449 shares at $1.10 on average. The purchase cost the insider an estimated $9.9 million.

    Important Earnings

    Top US earnings releases scheduled for today include Simulations Plus Inc. (NASDAQ: SLP). It will announce its Nov 2020 financial results. The company is expected to report earnings of $0.11 per share from revenues of $10.64M in the three-month period. 

    Kura Sushi USA Inc. (KRUS), due to announce earnings after the market closes today, is expected to report earnings of -$0.65 per share from revenues of $8.19M recently concluded three-month period.